BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 17289901)

  • 21. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
    Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
    Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
    J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
    Tong A; Zhang H; Li Z; Gou L; Wang Z; Wei H; Tang M; Liang S; Chen L; Huang C; Wei Y
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):791-802. PubMed ID: 17593366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
    Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
    Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
    Yamamoto S; Tanaka K; Sakimura R; Okada T; Nakamura T; Li Y; Takasaki M; Nakabeppu Y; Iwamoto Y
    Anticancer Res; 2008; 28(3A):1585-91. PubMed ID: 18630516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
    Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
    Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
    Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
    Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.